The sources of the opioid epidemic are complex, but one powerful motivator has been the pursuit of profit.
Articles on Big Pharma
Displaying 81 - 100 of 119 articles
The lack of transparency and accountability found in the hedge fund world is increasingly finding a home in the pharmaceutical sector, where more people care.
Tighter regulations of medicines and devices have prevented countless deaths and disabilities. But regulation can’t always protect us from harm.
Pharmaceutical companies aim to make a profit, but it took an industry insider to blow the whistle on some exorbitant drug costs the NHS was paying.
This project offers the tantalising possibility that plants containing drugs, such as agents to treat HIV, could be farmed on a small scale at low cost by communities that need them most.
Clinton, who named drug companies among her enemies in this week’s debate, is pushing populist-inspired policies that could hamper the flow of new medicines.
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
Five new European studies say dementia occurrence is stable or falling. Our panic may have been unnecessary.
Ever wonder how much it costs to develop a new drug? The Tufts Center for the Study of Drug Development estimates US$2.6 billion. But how accurate is this figure?
New ideas about what depression is and how to treat it are being held back by a lack of commercial interest.
Here’s what I remember. It was 14 years ago, and I was a junior doctor working in psychiatry. Some colleagues planned a dinner as an end-of-term celebration and, despite reasonable incomes, they decided…
Pfizer is like Woody Allen’s famous shark. It has to keep moving or it will die. And the drug company seems unable to keep moving by any means other than acquisitions. Its all-time best-selling drug, Lipitor…
Congratulations are in order. The pair have known each other for some time. But the relationship has now been formalised. Living as we do in modern times, both may have other relationships, but it’s still…
Ever since the time of the guillotine, doctors have been at the centre of the death penalty. Joseph Guillotin, the physician who suggested the device be used in 18th-century France, was actually against…
With billions to be made on the back of ill health and notable scandals and cover-ups in its history, it’s fair to say that many see the public face of the pharmaceutical industry as a mask for darker…
GlaxoSmithKline, one of the Big Five global pharmaceutical companies, this week gave the world an overdue Christmas present. Glaxo will stop paying doctors to promote its drugs and will no longer pay its…
An article published in the journal of the British Medical Association, BMJ, earlier this week illustrates a devastating problem with the “evidence base” in the academic medical literature. A large proportion…
China is in the midst of conducting a series of corruption investigations of pharmaceutical companies that have been operating in the country. It all started with the investigation of officials from pharmaceutical…
In 2001 I met David Graham, an official from the US Food and Drug Administration, in a car park in Washington. I wanted him to shed light on why the diabetes drug troglitazone, or Rezulin, had been available…
A study published today shows that clinical trials with industry sponsorship report greater benefits and fewer harmful side effects. In the discussion, the authors note that most reviews and guidelines…
Top contributors
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Senior Research Manager, University of Sydney and Honorary Assistant Professor, Bond University
-
Professor of Bioethics, Macquarie University
-
Associate Professor, School of Law, University of Canberra
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Assistant Professor of Resource Economics, UMass Amherst
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Macquarie University Research Fellow, Macquarie University
-
Professor of Medicine and Public Health, University of Colorado Anschutz
-
Adjunct associate, Lancaster University
-
Associate Professor Politics and Policy Studies, Deakin University
-
Health activist, Medreach Pty Ltd., Bond University
-
Research Fellow, Asia Pacific Social Impact Centre, The University of Melbourne
-
Professor of Accounting, Durham University
-
Associate professor, School of Biomedical Sciences, University of Leeds